Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy

Figure 1

Effect of bevacizumab (Bev) on glioma cell proliferation. After treatment with the indicated concentrations of Bev for 72 hours, cell proliferation rates were analyzed by MTT assay. The growth rates of cells with the IgG control were defined as 1.0 (*p < 0.05 vs the group treated with IgG control).

Back to article page